The identification of a specific mechanism of action of LSD1 in intratumoral CD8+ T cells also points to a promising avenue for targeting LSD1 in cancer immunotherapy through specifically disrupting the physical interaction between LSD1 and the long isoform of TCF1, a pivotal regulator driving the progenitor phenotype maintenance. This evidence concerns the gene KDM1A and cancer.